Research Article
Impact of Insurance Coverage on Outcomes in Primary Breast Sarcoma
Table 3
Baseline treatment characteristics by insurance coverage type.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In order to protect patient identity, some categories are combined, unknown categories with few patients are not shown, and cells with fewer than 11 patients are hidden; aPearson’s chi-squared value; bincludes residual tumor that is microscopic, macroscopic, and not otherwise specified; cincludes patients who received chemotherapy alone (n = 76), RT alone (n < 11), chemotherapy and RT (n < 11), and unknown (n = 16); dKruskal–Wallis value; abbreviations: BCS, breast-conserving surgery; NOS, not otherwise specified; NA, not applicable; RT, radiation therapy; tx, treatment; IQR, interquartile range. |